Cannabis for Cancer Patients in Australia — Symptom Relief, Nausea & How to Access (2026)

More than 165,000 Australians are diagnosed with cancer each year. For many of them, the most challenging aspect of treatment is not the disease itself but the side effects of the treatment — chemotherapy-induced nausea and vomiting, severe pain, appetite loss, fatigue, anxiety and insomnia that can make each day a physical and emotional ordeal.

Medicinal cannabis has emerged as one of the most prescribed supportive care options for Australian cancer patients over the past five years. Pain and nausea are the two most commonly approved indications for medicinal cannabis in Australia, and cancer patients account for a significant proportion of prescriptions under the TGA’s Special Access Scheme B (SAS-B).

This guide explains what cannabis can and cannot do for cancer patients, what the clinical evidence shows, and how to access medicinal cannabis legally in Australia.

What cannabis can help with — and what it cannot

Before going into detail, it is important to be clear about what cannabis does and does not offer cancer patients.

Where cannabis has evidence:

• Chemotherapy-induced nausea and vomiting (CINV) — the strongest evidence base
• Cancer-related pain — particularly neuropathic pain and bone pain
• Appetite stimulation and weight maintenance
• Sleep disruption
• Anxiety and mood disturbance related to cancer diagnosis and treatment

Where cannabis does not have evidence:

• Treating or curing cancer itself
• Shrinking tumours or affecting cancer progression in humans at clinically relevant doses
• Replacing conventional oncology treatment (chemotherapy, radiation, surgery, immunotherapy)

Preclinical studies in cell cultures and animal models have shown certain cannabinoids can affect cancer cell growth through various mechanisms. These findings have attracted significant attention. However, the doses required in cell culture studies are not achievable in humans without severe toxicity, and no clinical trial has demonstrated that cannabis treats cancer as a disease. Any claim that cannabis “cures cancer” is not supported by current evidence and should be treated with extreme scepticism.

Chemotherapy-induced nausea and vomiting (CINV)

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared side effects of cancer treatment — and one where cannabis has the most established evidence base.

The endocannabinoid system plays a direct role in nausea regulation. CB1 receptors are expressed throughout the gut and in brainstem regions (including the dorsal vagal complex) that control the nausea and vomiting reflex. THC acts on these receptors as an antiemetic — reducing the frequency and intensity of nausea.

Clinical evidence: A 2021 Cochrane systematic review of 23 randomised controlled trials involving more than 1,500 patients found that cannabinoids (including THC, nabilone and THC:CBD combinations) were more effective than placebo for CINV and broadly comparable to older antiemetic drugs, though with more side effects at higher doses. The evidence for cannabinoids versus newer antiemetics (ondansetron, dexamethasone) is less clear, and most oncology guidelines position cannabis as adjunct or second-line therapy.

Practical context: Many cancer patients experience CINV despite taking standard antiemetics. For this group — refractory CINV uncontrolled by first-line treatment — cannabis is now widely considered a clinically appropriate adjunct. Australian oncologists are increasingly comfortable co-prescribing.

Which products for CINV:

• THC-dominant oil or capsule taken 1–2 hours before chemotherapy infusion
• Starting dose: 2.5–5mg THC
• CBD alongside THC reduces psychoactive effects without impairing antiemetic action
• Vaporised THC can be used for breakthrough nausea (faster onset), though smoking is inappropriate in immunocompromised patients

Cancer-related pain

Pain is the most common symptom in cancer patients, affecting up to 70% at some stage of treatment. The mechanisms are varied — nociceptive pain from tissue damage, neuropathic pain from nerve compression or chemotherapy-induced peripheral neuropathy (CIPN), and inflammatory pain from tumour growth.

Cannabis works differently from opioids and NSAIDs, targeting distinct pain pathways:

• CB1 receptor agonism (primarily THC): Reduces the ascending pain signal in the spinal cord and brain. Produces analgesia through a mechanism entirely distinct from opioids — meaning there is no cross-tolerance.
• CB2 receptor agonism: Reduces neuroinflammation and peripheral sensitisation. Relevant for bone pain, inflammatory pain and neuropathic pain.
• TRPV1 desensitisation (CBD): Reduces peripheral pain signalling at the site of injury.
• Opioid system interaction: Cannabis and opioids have synergistic analgesic effects. Patients using both can often achieve adequate pain control at lower opioid doses — reducing opioid-related side effects.

Opioid-sparing effect: One of the most clinically significant findings in cancer pain research is that cannabis can reduce opioid requirements. A 2022 Australian retrospective study of medicinal cannabis patients found meaningful reductions in opioid analgesic doses in people using cannabis for pain. Reduced opioid use means less nausea, less constipation and less sedation from opioids themselves.

Chemotherapy-induced peripheral neuropathy (CIPN): Nerve damage causing numbness, tingling, burning pain and cold sensitivity in the hands and feet affects up to 80% of patients on certain chemotherapy regimens (paclitaxel, cisplatin, oxaliplatin). There is growing evidence that topical CBD and systemic cannabis may reduce CIPN severity, though the evidence base is still developing.

Appetite and weight

Unintentional weight loss and cachexia (wasting syndrome) are major challenges in cancer care. Loss of appetite makes it difficult to maintain the nutritional status needed to tolerate chemotherapy and support immune function.

THC is a known appetite stimulant, acting on CB1 receptors in the hypothalamic regions that regulate hunger. Dronabinol (synthetic THC) has been FDA-approved for cancer cachexia since the 1980s. However, clinical trials of synthetic THC for cancer cachexia have had mixed results, partly because appetite stimulation alone does not address the metabolic changes driving cachexia.

In practice, many Australian cancer patients report improved appetite and food enjoyment with THC-containing cannabis — particularly at low doses taken before meals. Whether this translates to meaningful weight maintenance depends on other factors, but even modest improvement in appetite can support treatment tolerance.

Sleep and anxiety in cancer patients

Up to 80% of cancer patients experience sleep disturbance, and up to 40% meet criteria for clinical anxiety at some point during treatment. Cannabis addresses both.

Sleep: High-CBD, low-THC oils for sleep maintenance; THC-containing oils at bedtime for sleep onset and nightmare suppression (relevant for patients with cancer-related PTSD). Read our sleep guide for more detail.

Anxiety: CBD-dominant products are preferred for daytime anxiety management in cancer patients — particularly those on medications with multiple drug interactions. CBD’s interaction potential is lower than THC’s and it does not impair daytime function. Read our anxiety guide.

Drug interactions: cannabis and cancer medications

This is a critical area for cancer patients. Many chemotherapy drugs are metabolised by the CYP450 enzyme system, and both CBD and THC inhibit certain CYP enzymes — particularly CYP3A4 and CYP2D6. This means cannabis can raise blood levels of some chemotherapy drugs, potentially increasing both efficacy and toxicity.

Cannabis compound	Primary enzyme affected	Chemotherapy drugs with interaction risk
CBD	CYP3A4, CYP2D6	Cyclophosphamide, paclitaxel, docetaxel, tamoxifen, imatinib
THC	CYP3A4	Similar range to CBD
Both	CYP2C9	Warfarin, some anti-epileptics used in brain tumour patients

Practical guidance: Always disclose cannabis use to your oncologist before starting. This is not a reason to avoid cannabis — it is a reason to monitor. Your oncologist may adjust chemotherapy timing, dosing or monitoring schedules. Most interactions are manageable, and the benefits of cannabis for CINV and pain often outweigh the complexity of managing them.

Product types most commonly used by Australian cancer patients

Product	Best for	Onset	Duration
THC:CBD oil (sublingual)	Pain, nausea, sleep	15–45 min	4–8 hrs
CBD oil (swallowed)	Anxiety, daytime use, CIPN	45–90 min	6–10 hrs
THC capsule	Overnight pain and sleep	60–120 min	8–12 hrs
Vaporised flower	Acute nausea, breakthrough pain	5–15 min	1–3 hrs
CBD topical	Localised CIPN, skin irritation	15–30 min	2–4 hrs

Avoid edibles (other than capsules) for cancer patients on immunosuppressive therapy — the unpredictable onset and dose variability creates unnecessary risk in an already complex pharmacological situation.

Accessing medicinal cannabis as a cancer patient in Australia

Cancer patients are among the most straightforwardly eligible groups for medicinal cannabis prescriptions in Australia. Pain, nausea, anorexia and insomnia are all accepted indications under the TGA’s SAS-B framework, and most oncologists and GPs are now familiar with the prescribing process.

Step 1: Speak to your oncologist or GP Your oncologist is the best starting point — they understand your specific treatment regimen, can identify interactions, and can prescribe or refer to a medicinal cannabis prescriber. If your oncologist is not comfortable prescribing, ask for a referral to a palliative care specialist, who typically have strong medicinal cannabis expertise.

Step 2: Telehealth platforms If you prefer to keep cannabis management separate from your oncology care, telehealth platforms including Alternaleaf, Polln and Leafio can provide consultations and prescriptions. Bring documentation of your diagnosis and current treatment plan.

Step 3: What to expect at the consultation The prescriber will review your cancer diagnosis, current chemotherapy or treatment regimen, other medications, and the specific symptoms you want to address. They will recommend a starting product and dose, and arrange prescription dispensing — typically home delivery within 2–7 business days.

Cost: Medicinal cannabis is not PBS-listed. Typical monthly cost: $100–300 depending on product and dose. Some private health insurance policies offer partial reimbursement. Palliative care patients may access specific support — ask your care team.

Frequently asked questions

Can cannabis cure cancer? No. There is no clinical evidence that cannabis treats or cures cancer in humans. Preclinical data from cell cultures and animal models is not translatable to human cancer treatment at this time. Cannabis is a valuable supportive care tool for managing cancer symptoms and treatment side effects — not a cancer treatment itself.

Is medicinal cannabis safe to use during chemotherapy? For most cancer patients, yes — with oncologist oversight. The key considerations are drug interactions (CBD and THC inhibit CYP450 enzymes that metabolise some chemotherapy drugs) and immune status (immunocompromised patients should avoid smoking or vaporising; oils and capsules are safer formats). Always disclose cannabis use to your oncologist.

Does cannabis help with chemotherapy nausea? Yes — this is the most robustly evidenced use of cannabis in cancer care. THC-containing products reduce CINV frequency and intensity, particularly in patients with inadequate control from standard antiemetics. It is best used as an adjunct to, not a replacement for, conventional antiemetics.

Can cancer patients get medicinal cannabis on the PBS in Australia? No. Medicinal cannabis is not listed on the PBS. Cancer patients pay out of pocket, typically $100–300 per month. Patients receiving palliative care should discuss support options with their care team.

Will cannabis help with cancer pain? For many patients, yes. Cannabis is particularly effective for neuropathic pain (including CIPN), inflammatory bone pain and anxiety-amplified pain. An important effect is opioid-sparing — cannabis can allow adequate pain control at lower opioid doses, reducing opioid side effects. Effectiveness varies by patient and cancer type; discuss with your oncologist.

What is the best cannabis product for cancer patients? The right product depends on the primary symptoms. For nausea: THC-dominant oil before chemotherapy. For pain: THC:CBD balanced oil taken consistently. For anxiety: CBD-dominant oil morning and midday. For sleep: CBD or balanced oil at bedtime. Your oncologist or medicinal cannabis prescriber can tailor a regimen to your specific treatment schedule.

Can cannabis help with the emotional side of a cancer diagnosis? Yes. The anxiety, depression and existential distress that frequently accompany a cancer diagnosis are among the indications best supported by CBD evidence. The research on CBD for anxiety is applicable to cancer-related anxiety, and CBD’s non-impairment profile makes it compatible with maintaining quality of life during treatment.

Should I tell my oncologist I am using cannabis? Absolutely. Cannabis interacts with chemotherapy drugs via the CYP450 system and can affect how your body processes treatment. Your oncologist needs this information to ensure your safety. In Australia, most oncology centres now have a standard question about cannabis use in intake forms — disclosure is both expected and protective.